INTS

Company Overview — What Does INTENSITY THERAPEUTICS, INC. Do?

Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. One challenge that we have identified with current intratumoral (IT) treatment approaches is that a tumor’s lipophilic, high fat and pressurized microenvironment does not effectively absorb water-based products. We believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments that formulate their product candidates by injecting aqueous products (regardless of the mechanism or approach, i.e. the stimulation of an inflammatory response or efforts to attract immune cells into a hostile live tumor). Accordingly, there remains a continued unmet need for the development of direct IT therapies for solid tumors that provide high local killing efficacy coupled with nontoxic systemic anti-cancer effects. We believe we have created a product candidate with the necessary chemistry to overcome this local delivery challenge. Evidence shows the mechanism of tumor killing achieved by our drug candidate also leads to systemic immune activation in certain cancers. Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct components: one part is soluble in water and the other is soluble in fat or oils. When an amphiphilic compound is mixed with therapeutic agents, such as chemotherapies, the agents also become soluble in both fat and water. Our product candidates include novel formulations consisting of potent anti-cancer drugs mixed together with these amphiphilic agents. Our lead product candidate, INT230-6, consists of two proven anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed with the amphiphilic molecule (SHAO) — all in one vial. The anti-cancer agents, cisplatin and vinblastine sulfate, used in our product candidate are both generic. These agents are available to purchase in bulk supply commercially. The United States Food & Drug Administration (the “FDA”) has approved both drugs as intravenous agents for several types of cancers. Cisplatin was first approved in 1978 for testicular cancer. Per the product labeling, cisplatin’s approved indications include treatment of testicular, ovarian and bladder cancer. The drug is also used widely in several other cancers including pancreatic and bile duct cancer. Vinblastine sulfate was first approved in 1965. Per the product labeling, vinblastine sulfate’s approved indications include treatment of generalized Hodgkin’s disease, lymphocytic lymphoma, advanced carcinoma of the testis, and Kaposi’s sarcoma. The drug is also used in breast and lung cancer. In 2017, we initiated a Phase 1/2 dose escalation study using INT230-6 in the United States under an investigational new drug application (“IND”) authorized by the FDA and in Canada following receipt of a no objection letter from Health Canada. The study, IT-01, is exploring the safety and efficacy of INT230-6 in patients with refractory or metastatic cancers. We completed the Phase 1 dose escalation portion of this study. The Company has annually submitted safety data from all clinical trials to the FDA and Health Canada. Both regulatory agencies have reviewed the data and have permitted the Company to continue all clinical development programs without comment. The majority of drug related adverse events have been low grade (grade 1 or 2). As of October 20, 2021, a total of 11 patients out of 95 (12%) have had a grade 3 treatment related adverse event in study IT-01. The grade 3 events have been abdominal pain (4 patients), localized tumor pain (2 patients), fatigue (2 patients), and 1 case each of vomiting, dehydration and dizziness. There have been no grade 4 or 5 treatment related adverse events reported. We are currently conducting the Phase 2 portion of the trial, which consists of several different expansion cohorts. Four of the cohorts combine our product candidate with Merck’s Keytruda® (pembrolizumab) and 3 arms combine our drug candidate with Bristol-Myers Squibb’s drug Yervoy® (ipilimumab). We are also evaluating INT230-6 in a Phase 2 study (the INVINCIBLE study) in Canada as a treatment prior to surgery in early stage breast cancer. Based on the broad range of data that we have generated from our preclinical experiments and clinical trials, we have observed that INT230-6 disperses widely throughout injected tumors, is absorbed well, penetrates and delivers the potent agents into tumor cells to kill them and activates a systemic immune response to fight the cancer. Our treatment approach utilizes intratumoral administration of INT230-6 to selectively induce tumor cell death and elicit an innate and adaptive anti-tumor immune response. Following injection of our product candidate, the tumors become highly necrotic, meaning that cancer cells die. After injection of INT230-6, tumors also become more amenable to immune cell infiltration. The tumor-killing process creates antigens, which are substances from the patient’s tumor that improve the recognition of the cancer by immune cells. While our product candidate is administered directly into the tumor, we have also observed in our preclinical studies and in our clinical trials that injections of INT230-6 can lead to a systemic immune response that attacks distal, uninjected tumors, a result known as an “abscopal” effect. Data generated in our trials show that our patented and patent pending drugs can extend life with less toxicity. Between the metastatic study IT-01 and the INVINCIBLE study we have treated over 115 patients as of September 30, 2021. Intensity Therapeutics, Inc., a Delaware corporation, was incorporated on November 30, 2012, upon the conversion of its predecessor Intensity Therapeutics LLC. Our principal executive offices are located at 61 Wilton Road, 3rd Floor, Westport, CT. INTENSITY THERAPEUTICS, INC. (INTS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Lewis H. Bender and employs approximately 2 people. With a market capitalization of $14M, INTS is one of the notable companies in the Healthcare sector.

INTENSITY THERAPEUTICS, INC. (INTS) Stock Rating — Reduce (April 2026)

As of April 2026, INTENSITY THERAPEUTICS, INC. receives a Reduce rating with a composite score of 36.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.INTS ranks #3,128 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, INTENSITY THERAPEUTICS, INC. ranks #460 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INTS Stock Price and 52-Week Range

INTENSITY THERAPEUTICS, INC. (INTS) currently trades at $5.56. The stock lost $0.04 (0.7%) in the most recent trading session. The 52-week high for INTS is $8.05, which means the stock is currently trading -31.0% from its annual peak. The 52-week low is $0.19, putting the stock 2900.5% above its annual trough. Recent trading volume was 16K shares, suggesting relatively thin trading activity.

Is INTS Overvalued or Undervalued? — Valuation Analysis

INTENSITY THERAPEUTICS, INC. (INTS) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.12x, versus the sector average of 2.75x.

At current multiples, INTENSITY THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

INTENSITY THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

INTENSITY THERAPEUTICS, INC. (INTS) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -101.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -85.6% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INTS Debt, Balance Sheet, and Financial Health

INTENSITY THERAPEUTICS, INC. has a debt-to-equity ratio of 19.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.92x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $7M.

INTS has a beta of -3.24, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for INTENSITY THERAPEUTICS, INC. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

INTENSITY THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, INTENSITY THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-8.56. Net income for the quarter was $-12M. Operating income came in at $-12M.

In FY 2025, INTENSITY THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-8.56. Net income for the quarter was $-12M. Operating income came in at $-12M.

In Q3 2025, INTENSITY THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.06. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, INTENSITY THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-3M. Operating income came in at $-3M.

Over the past 8 quarters, INTENSITY THERAPEUTICS, INC. has experienced revenue contraction from $0 to $0. Investors analyzing INTS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INTS Dividend Yield and Income Analysis

INTENSITY THERAPEUTICS, INC. (INTS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INTS Momentum and Technical Analysis Profile

INTENSITY THERAPEUTICS, INC. (INTS) has a momentum factor score of 79/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

INTS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, INTENSITY THERAPEUTICS, INC. (INTS) ranks #460 out of 838 stocks based on the Blank Capital composite score. This places INTS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INTS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INTS vs S&P 500 (SPY) comparison to assess how INTENSITY THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

INTS Next Earnings Date

No upcoming earnings date has been announced for INTENSITY THERAPEUTICS, INC. (INTS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INTS? — Investment Thesis Summary

The quantitative profile for INTENSITY THERAPEUTICS, INC. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Price momentum is positive at 79/100, suggesting the trend favors buyers. High volatility (stability score 33/100) increases portfolio risk.

In summary, INTENSITY THERAPEUTICS, INC. (INTS) earns a Reduce rating with a composite score of 36.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INTS stock.

Related Resources for INTS Investors

Explore more research and tools: INTS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INTS head-to-head with peers: INTS vs AZN, INTS vs SLGL, INTS vs VMD.